Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]
In development
Reference number: GID-HST10063
Expected publication date: TBC
Following a request by the company, UCB Pharma, the evaluation has been paused.
The committee meeting planned for 19 March 2026 will not go ahead.
NICE will continue discussions with the company and will provide an update in Q1 2026 regarding new timelines.